300030 Stock Overview
Engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Improve Medical Instruments Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.70 |
| 52 Week High | CN¥8.63 |
| 52 Week Low | CN¥3.31 |
| Beta | 0.19 |
| 11 Month Change | -0.54% |
| 3 Month Change | -20.43% |
| 1 Year Change | -50.27% |
| 33 Year Change | -67.66% |
| 5 Year Change | -29.12% |
| Change since IPO | -56.46% |
Recent News & Updates
Revenues Working Against Improve Medical Instruments Co., Ltd.'s (SZSE:300030) Share Price Following 26% Dive
Jun 06
A Look At The Fair Value Of Improve Medical Instruments Co., Ltd. (SZSE:300030)
Jun 04Recent updates
Revenues Working Against Improve Medical Instruments Co., Ltd.'s (SZSE:300030) Share Price Following 26% Dive
Jun 06A Look At The Fair Value Of Improve Medical Instruments Co., Ltd. (SZSE:300030)
Jun 04Benign Growth For Improve Medical Instruments Co., Ltd. (SZSE:300030) Underpins Stock's 27% Plummet
Apr 16Improve Medical Instruments Co., Ltd.'s (SZSE:300030) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 26Shareholder Returns
| 300030 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 0.5% | -4.4% | -3.0% |
| 1Y | -50.3% | -41.5% | -21.8% |
Return vs Industry: 300030 underperformed the CN Life Sciences industry which returned -41.5% over the past year.
Return vs Market: 300030 underperformed the CN Market which returned -21.8% over the past year.
Price Volatility
| 300030 volatility | |
|---|---|
| 300030 Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.8% |
Stable Share Price: 300030's share price has been volatile over the past 3 months.
Volatility Over Time: 300030's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 936 | Guanhua Deng | www.improve-medical.com |
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising urine, feces, and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company also offers offers specimen processing equipment, including evacuated blood collection systems, evacuated blood collection tubes, multi-sample needles, blood collection sets, tourniquets and disposable tourniquets, urine collection systems, and holders under IMPROVACUTER brand name; and IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, IMPROSAFE safety blood collection needles, IMPROSWAB microbiological transport swabs, IMPROVE sharps containers, liquid biopsy pre-analytical systems, etc. In addition, it provides clinical nursing products, including automatic, handheld, pulsewave, and smart wireless blood pressure monitors; and intelligent management solutions, such as blood collection tube preparation systems, friendly graphic user interfaces, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels, as well as CryoMax vials and liquid nitrogen freezing storage boxes.
Improve Medical Instruments Co., Ltd. Fundamentals Summary
| 300030 fundamental statistics | |
|---|---|
| Market cap | CN¥1.12b |
| Earnings (TTM) | -CN¥80.03m |
| Revenue (TTM) | CN¥627.21m |
1.8x
P/S Ratio-14.3x
P/E RatioIs 300030 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300030 income statement (TTM) | |
|---|---|
| Revenue | CN¥627.21m |
| Cost of Revenue | CN¥399.33m |
| Gross Profit | CN¥227.88m |
| Other Expenses | CN¥307.91m |
| Earnings | -CN¥80.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 15, 2024
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 36.33% |
| Net Profit Margin | -12.76% |
| Debt/Equity Ratio | 53.2% |
How did 300030 perform over the long term?
See historical performance and comparison